Search

When Matt Halfill was a kid, his parents sent him to a charter school in Fresno, Calif., where he got a tremendously valuable education-about footwear. 'That wasn't the most advantaged [...]

When Matt Halfill was a kid, his parents sent him to a charter school in Fresno, Calif., where he got a tremendously valuable education-about footwear. 'That wasn't the most advantaged [...]

Late last year, after the market crashed, Travelocity's Victoria Treyger took a close look at her Google search results and noticed that far more than stock prices had changed. Consumers, [...]

If you want to know what the current economy holds in store for the advertising industry, you might consider what happened after Galileo made his famous climb to the top [...]

When Whirlpool launched its KltchenAid Series II line of appliances in 2007, the company was taking a bigger-than-usual gamble. Whirlpool's designers didn't just imbue the Series II--a refrigerator, microwave, range, [...]

The $550 billion or so consumer firms spent on retail marketing in 2006 far outstrips the $139 billion they put behind advertising that year, but you don't hear much about [...]

If you want to get a taste of state-of-the-art engagement marketing circa 2007, visit Pampers.com. Procter & Gamble launched its first Web site for Pampers in 1996, but at that [...]

UNLESS YOU'VE BEEN hiding under the desk in your office, you've no doubt heard some of the ubiquitous talk that's been floating around lately about whether the Chief Marketing Officer--much [...]

It's a beautiful Indian summer day in Paramus, NJ., sunny and 60 degrees, perhaps a bit warmer than residents might expect for mid-October. The abundant oaks and maples in this [...]

Chances are, if you're reading this story you already know what YouTube is. Perhaps you've also heard about lonelygirl15, the exploding Mentos, the site's 100 million daily downloads, its 63% [...]

Bob Stohrer wants Virgin Mobile to be an open-source brand. By his definition, that means he wants consumers and marketers to have an equal say as to what the brand [...]

Hgih schools are always abuzz with talk od one kind or another: sports, music, clothes and whatever else teens consider indispensible at any given time. But last year, one piece [...]

the annals of business are stocked with stories of mighty blue chip firms that somehow lost their way. Think Coca-Cola before Roberto Goizueta or IBM before Lou Gerstner, or Apple [...]

despite his job, or maybe because of it, Geoffrey Frost isn't crazy about the word 'phone.' Motorola's chief marketing officer prefers to use terms like 'the device formerly known as [...]

In 2003, executives at Courvoisier were toasting their good fortune. Thanks to a ditty called 'Pass the Courvoisier,' sales of the cognac were racing up the charts. The hit Busta [...]

In the 1920s, Austin Kness built a better mousetrap. The Kness Ketch-All Multiple Mousetrap uses multiple bait to trap several mice at once. To this day, it's the main source [...]

In the dot-com era, there was a mania for linking Internet sales to TV based on a simple premise: Wouldn't it be cool if you could see Jennifer Anis ton [...]

Mary Engle is all for free markets. She doesn't think the government should tell companies how to advertise, even to children. But she admits that there are times when she [...]

Call them mercenary, or Super, CMOs. They parachute in from company to company, from industry to industry, firing and hiring ad agencies and staff. They make noise. They launch memorable [...]

Frontier Airlines' fleet of planes, with their tailfins that feature renderings of cats, rabbits and foxes, often draws a crowd of gawkers at Denver International Airport. This surprisingly useful fact [...]

There are 50 state attorneys general in the United States. Here's a quick test: Name three. Chances are, no matter where you live, Eliot Spitzer topped the list. Since taking [...]

Scoring big at the box office is as crucial to Madison Avenue today as it is to Hollywood. Consumer marketers need to know what new campaigns--and new products--have done for [...]

In a recent commercial for Microsoft.Net, an eccentric British record company executive thinks he has hit upon the perfect sales pitch. Seated at his laptop, his younger employee (whom he [...]

With consumers flocking to broadband and AOL's future in doubt, all eyes are on entertainment unit chief Kevin Conroy's plan to offer users previews of movies and music on the [...]

One of few firms to survive the tech crash, Dell won over the consumer market with a savvy business model and its ads' unlikely teen hero. The computer industry is [...]

Building brands in America today requires an understanding of both cultural and market forces. With a nation evenly split into 'Red' and 'Blue' camps, how far can giants in retail, [...]

Tyson Foods spent approximately $25 million on media last year. A percentage of that time was paid for with drumsticks and breasts. Tyson's payment for its spot TV portion, via [...]

Waltham, Mass.-Computer networks, once the sole domain of high-end specialists in the corporate market, are moving quickly and simply into the home, with the backing of forthcoming wireless projects by […]

If logic is any guide, the chief executive officer of the biggest retailer should be paid more than any other CEO, right? Wrong. While Wal-Mart CEO David Glass received $1.17 […]

Background. Although there have been occasional reports of improved response with greater doses of irradiation for unresected brain metastases, dose escalation has not been systematically studied in a cohort of patients with solitary brain metastasis. The current study examines this group of patients to evaluate dose escalation using accelerated hyperfractionated radiation therapy (XRT) with regard to survival, patterns of failure and toxicity. Method. Radiation Therapy Oncology Group (RTOG) 85-28, a Phase I/II randomized trial of accelerated hyperfractionated XRT for patients with unresected supratentorial brain metastases, enrolled 153 patients with solitary brain metastasis. Whole brain dose was 32 Gray (Gy) administered in 1.6 Gy fractions twice a day with an interfraction interval of 4-8 hours. Boost dose wa escalated to total doses of 48.0, 54.4, 64.0, and 70.4 Gy. Results. Acute and late toxicities were acceptable. The median survival time and 1-year survival rates were 4.9 months and 20% a 48 Gy; 5.4 months and 33% at 54.4 Gy; 7.2 months and 28% at 64 Gy; and 8.2 months and 37% at 70.4 Gy, respectively. Comparison of the upper three dose treatment arms to the 48 Gy treatment arm revealed a superior survival time with doses of 54.4 Gy and greater (P = 0.05). Improvement in neurologic function appeared to increase with dose escalation, with 25% of patients experiencing improvement at doses of 48 Gy, 38% at 54.4 Gy 50% at 64 Gy, and 63% at 70.4 Gy (P = not significant). Conclusion. A radiation dose response for survival time appears to exist with the use of accelerated hyperfractionated XRT for patients with unresected solitary brain metastasis. Cancer 1993; 71:1362-7.

If you're a marketer who has steered clear of Twitter, your (non)strategy may be paying off! It's possible that this Twitter thing may just take care of itself. In the [...]

Forty-six cases of solitary plasmacytoma were reviewed for response to radiation and progression to multiple myeloma. Cases were classified as solitary plasmacytomas of bone (SPB) (32 cases) or extramedullary plasmacytomas (EP) (14 cases). There was an overall 93% response rate of the tumor to radiation therapy: 62% had a complete response after radiation therapy, whereas 31% had a partial response. Conversion to multiple myeloma was influenced by the type of plasmacytoma; 53% of the patients with SPB converting to myeloma versus 36% of the patients with EP. Time from diagnosis to conversion for patients with SPB showed no evidence of plateau, with conversion continuing to occur even after 17 years. The median survival time for patients after conversion to myeloma was 14.5 months and was not affected by time to conversion. Serum protein level, presence of monoclonal gammopathy, and size of primary lesion were of some prognostic significance in predicting conversion to myeloma. Adjuvant chemotherapy did not affect the incidence of conversion but did appear to delay conversion to myeloma. Seven patients in whom multiple sequential solitary plasmacytomas developed formed a distinct subset, with a median time to a second plasmacytoma of 63 months. In three of these patients, conversion to myeloma occurred subsequently. This study supports the idea of EP having a lower incidence of conversion to myeloma and a different natural history from SPB, with SPB likely to be multiple myeloma in evolution. Cancer 1992; 69:1513-1517.

CHIEF MARKETING OFFICERS often fall prey to the belief that others are ahead of the queue in staking claims in new media. Two years ago, a CMO might have felt [...]

CHIEF MARKETING OFFICERS often fall prey to the belief that others are ahead of the queue in staking claims in new media. Two years ago, a CMO might have felt [...]

Experience has established that Hodgkin's disease is especially susceptible to radiation, and that radiation alone leads to a high survival rate for early-stage Hodgkin's disease. Over the years, many patients have undergone staging laparotomy, the surgical examination of the abdomen to precisely determine the stage of disease. This has led to great knowledge about the natural history and progression of Hodgkin's disease. However, now that this knowledge has been accumulated, it is unclear that continuing the practice of staging laparotomy provides any benefit to the patient. The staging laparotomy only provides benefit if therapeutic decisions are based on the observations made during the surgery. Since the surgery itself has substantial risks and can result in substantial illness, a review of 94 cases of Hodgkin's disease was conducted to evaluate any potential contribution of staging laparotomy. All 94 patients had Stage I or Stage II disease and were treated with radiation alone. Fifty-two patients underwent a staging laparotomy. All patients achieved an initial complete response, but 10 patients relapsed within 5 years. Overall, the five-year disease-free survival was 86 percent, a rate that compares favorably with other reported survival rates for early-stage Hodgkin's disease. No significant differences were observed between the patients who underwent laparotomy and those who did not. These results indicate that patients with satisfactory clinical indications of early-stage Hodgkin's disease need not be subjected to the discomfort and risks of a staging laparotomy prior to treatment for their disease. (Consumer Summary produced by Reliance Medical Information, Inc.)

SALT IS ESSENTIAL FOR LIFE, BUT EAT TOO MUCH OF IT and it may kill you. This is not news. The prevailing theory is that salt forces your body to [...]

Like their brethren whose wares line the noncomestible aisles, big food companies have been pigging out on media lately. In 2007, the industry increased its ad outlay 7.6% over the [...]